Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Nanomedicine (Lond). 2012 Oct 17;8(5):687–698. doi: 10.2217/nnm.12.134

Figure 6.

Figure 6

Cytotoxicity of I&C targeted NPs (NPI&C) in LNCaP cells compared irinotecan targeted NPs (NPI) (A) and cisplatin targeted NPs (NPC) (B). Dual-drug NPs had an IC50 10.6 times and 3.6 times lower than cisplatin and irinotecan NPs, respectively. (C) Combination index determined by Talay and Chou method at ED80. According to the metric 0.20 corresponds to strong synergism. The NPs used had a final irinotecan to cisplatin ratio of 1.5:1 by mole.